Cytokines | Control | LPS | LPS + Bev 1 | LPS + Bev 2 | Bev |
|---|
IL-6 (pg/ml)
| 0.0 ± 0.0 | 2,054.3 ± 98.6 | 1,477.8 ± 44.6* | 1,281.4 ± 25.9* | 0.0 ± 0.0 |
MCP-1 (ng/ml)
| 1.42 ± 0.02 | 13.71 ± 0.18 | 10.74 ± 0.25 | 10.05 ± 0.13* | 0.87 ± 0.02 |
RANTES (pg/ml)
| 0.0 ± 0.0 | 286.2 ± 4.0 | 240.6 ± 3.3 | 201.7 ± 17.2* | 0.0 ± 0.0 |
- Data are expressed as means ± SD. The levels of IL-6, MCP-1 and RANTES in HUVECs after treatment with LPS (LPS group), LPS + Bev (Bev 1 at 25 μg/ml Bev, and Bev 2 at 50 μg/ml Bev), or Bev-only group (50 μg/ml Bev). *P <0.01 when compared to the group of LPS (n = 4).
- Bev, bevacizumab; HUVECs, human umbilical vein endothelial cells; LPS, lipopolysaccharide; MCP-1, monocyte chemotactic protein-1; RANTES, regulated on activation, normal T-cell expressed and secreted; SD, standard deviation.
